Join Magnolia Market Access at the World Orphan Drug Congress USA
Orphan Drug Access Strategy in a Changing Policy Environment
The World Orphan Drug Congress USA brings together leaders across the rare disease and orphan drug ecosystem to discuss the policy, access, pricing, reimbursement, commercialization, and patient support issues shaping the future of rare disease treatment.
As policy and pricing dynamics continue to evolve, orphan drug manufacturers are facing new questions about how to plan for access, demonstrate value, and support patients in an increasingly complex environment. While some policy initiatives may appear only indirectly related to orphan drugs, their downstream effects can have meaningful implications for commercialization, reimbursement, and patient access.
World Orphan Drug Congress USA 2026
June 9–11, 2026
Thomas M. Menino Convention & Exhibition Center
Boston, MA
Featured Session
Staying Ahead of the Curve: Strategic Responses to a Shifting Policy and Pricing Landscape for Orphan Drug
Date: June 9, 2026
Time: 3:00 PM ET
Workshops – Investment & Impact
With ongoing policy and pricing changes, many manufacturers are asking what these shifts mean for orphan drugs. While some initiatives, including demonstration projects, may appear only indirectly related, their downstream effects can have meaningful implications for orphan drug access, reimbursement, commercialization, and patient support.
In this session, leaders from Magnolia Market Access will explore how manufacturers can anticipate and respond to shifting policy, pricing, and market access pressures affecting orphan drug development and commercialization.
The discussion will cover:
Speakers:
Track Session
From Value to Volume: Comparing HTA and Market-Driven Pricing for Orphan Drugs in Europe and the United States
Date: June 11, 2026
Time: 2:40 PM ET
Track: Commercialization
Orphan drug pricing takes shape very differently across the Atlantic. In Europe, HTA-driven assessments, value frameworks, and negotiated reimbursement define price and access, while in the United States, a market-driven environment with limited price controls creates higher pricing flexibility but broader variation in patient access.
This panel will examine how these contrasting systems shape launch strategy, patient availability, long-term sustainability, and incentives for innovation, as well as what lessons each region can learn from the other.
The discussion will cover:
Schedule a one-on-one meeting with the Magnolia Market Access team to discuss how policy, pricing, reimbursement, and patient access dynamics may impact your orphan drug strategy. Our team can help identify market access considerations earlier, pressure-test commercialization assumptions, and build strategies that support sustainable access for rare disease therapies.
"*" indicates required fields